A Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose and Single Dose Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Subjects
Latest Information Update: 27 Aug 2021
Price :
$35 *
At a glance
- Drugs E 2730 (Primary)
- Indications Epilepsy; Neurological disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Inc
- 20 Aug 2021 Status changed from recruiting to completed.
- 17 Feb 2021 Planned End Date changed from 27 Jun 2021 to 19 Jun 2021.
- 17 Feb 2021 Planned primary completion date changed from 27 Jun 2021 to 19 Jun 2021.